Sample records for VIRUS DE VACUNA (vaccinia virus)
from WorldWideScience.org

Sample records 1 - 20 shown. Select sample records:



1

Vaccinia Virus E3 Protein Prevents the Antiviral Action of ISG15

Guerra, Susana; Cáceres, Ana; Knobeloch, Klaus-Peter; Horak, Ivan; Esteban, Mariano

DRIVER (Spanish)

2

Vaccinia Virus E3 Protein Prevents the Antiviral Action of ISG15

Guerra, Susana; Cáceres, Ana; Knobeloch, Klaus-Peter; Horak, Ivan; Esteban, Mariano
2008-07-04

Digital.CSIC (Spain)

3

Contribución de la quinasa B1 a la patogénesis del virus vaccinia

Ribeiro dos Santos, Claudio

Dir: Pedro A. Lazo-Zbikowski | Peer reviewed

DRIVER (Spanish)

6

The vaccinia virus B1R kinase induces p53 downregulation by an mdm2-dependent mechanism

Santos, C.R.; Vega, F.M.; Blanco, Sandra; Barcia, R.; Lazo, Pedro A.
2004-01-01

Digital.CSIC (Spain)

8

The vaccinia virus B1R kinase interacts with JIP1 and modulates c-Jun dependent signalling

Santos, C.R.; Blanco, Sandra; Sevilla Hernández, Ana; Lazo, Pedro A.
2006-01-01

Digital.CSIC (Spain)

9

Diseño y construcción de vectores de transferencia para la obtención de virus vaccinia Ankara modificado (MVA) recombinantes/ Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)

Ferrer, M. F.; Zanetti, F. A.; Calamante, G.
2007-09-01

Resumen en español El virus vaccinia Ankara modificado (MVA) constituye un buen candidato para el desarrollo de vectores virales de expresión no replicativos porque no replica en la mayoría de las células de mamíferos. Para la producción de MVA recombinantes es fundamental disponer de vectores de transferencia que, por recombinación homóloga con el genoma viral, permitan introducir los genes de interés en regiones no esenciales para la replicación in vitro. En este trabajo se dise� (mas) �aron y obtuvieron los vectores de transferencia denominados VT-MHA y VT-MTK que portan las regiones correspondientes a las posiciones 1-303 y 608-948 del gen MVA165R y 1-244 y 325-534 del gen MVA086R, respectivamente, las que flanquean un sitio de clonado múltiple para la inserción de los genes foráneos. En dichos vectores se clonaron los casetes para la expresión de los genes lac Z o uid A, y la actividad de las enzimas marcadoras b-galactosidasa y b-glucuronidasa se confirmó in situ. Además, utilizando el vector denominado VT-MTK-GUS, se obtuvieron y aislaron MVA recombinantes puros que portan y expresan el gen uid A. Los resultados obtenidos constituyen las herramientas básicas para establecer la metodología de obtención de MVA recombinantes, con el propósito de desarrollar localmente vectores virales no replicativos candidatos a vacunas. Resumen en inglés Modified Vaccinia virus Ankara (MVA) constitutes a good candidate for the development of non-replicative expression viral vectors because it does not replicate in most of mammalian cells. It is essential, for the production of recombinant MVA, the availability of transfer vectors which allow the introduction of desired genes into non-essential regions for in vitro viral replication, by homologous recombination with the viral genome. In the present work, the transfer vecto (mas) rs named VT-MHA and VT-MTK were designed and obtained. They carried genomic regions corresponding to 1- 303 and 608-948 positions of the MVA165R gene and 1-244 and 325-534 of the MVA086R gene, respectively, which flank a multiple cloning site for the insertion of foreign genes. In these vectors, the cassettes for the expression of lac Z or uid A genes were cloned, and the activity of the marker enzymes b-galactosidase and b-glucuronidase was confirmed in situ. Furthermore, the vector named VT-MTK-GUS was used to obtain and isolate pure recombinant MVA, which carried and expressed the uid A gene. The results herein constitute the basic tools for establishing the methodology to obtain recombinant MVA with the purpose of locally developing non-replicative viral vectors as candidate vaccines.

Scientific Electronic Library Online (Spanish)

10

Recombinant vectors based on the Modified Vaccinia Ankara (MVA) virus as vaccines against leishmaniasis | Vectores recombinantes basados en el virus vaccinia modificado de Ankara (MVA) como vacunas contra la leishmaniasis

Pérez Jiménez, Eva; Larraga Rodríguez de Vera, Vicente Emilio; Esteban, Mariano

Filing Date: 2006-07-28. --Priority Data: ES P200501886 (2005-07-30) | [EN]The invention relates to recombinant vectors based on the Modified Vaccinia Ankara (MVA) virus as vaccines against leishmaniasis. The inventive vectors contain sequences encoding the LACK protein, which are preferably inserte...

DRIVER (Spanish)

11

P17-07. Insertion of a vaccinia virus host range (hr) gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens

Nájera García, José Luis; Gómez, Carmen E.; García-Arriaza, J.; Esteban, Mariano
2009-10-01

Digital.CSIC (Spain)

12

P17-23. Enhanced expression of HIV antigens and improved antigen presentation after infection with replication competent attenuated vaccinia virus in vitro

Quakkelaar, E.; Redeker, A.; Loof, N.; Perdiguero, B.; Heinen, P.; Nieto, J.; Esteban, Mariano; Kibler, K.; Jacobs, B.; Pantaleo, Giuseppe; Melief, C.
2009-10-01

Digital.CSIC (Spain)

14

Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a Vaccinia virus recombinant

Gómez, Carmen E.; Vandermeeren, Andrée M.; García López, María Ángeles; Domingo-Gil, Elena; Esteban, Mariano
2005-09-12

Digital.CSIC (Spain)

15

Membrane cell fusion activity of the vaccinia virus A17–A27 protein complex

Kochan, Grazyna; Escors Murugarren, David; González, José Manuel; Casasnovas, José María; Esteban, Mariano

16 pages, 8 figures.-- PMID: 17708756 [PubMed].-- Printed version published on Jan 2008. | Vaccinia virus enters cells by endocytosis and via a membrane fusion mechanism mediated by viral envelope protein complexes. While several proteins have been implicated in the entry/fusion event, there is no d...

DRIVER (Spanish)

16

Membrane cell fusion activity of the vaccinia virus A17–A27 protein complex

Kochan, Grazyna; Escors Murugarren, David; González, José Manuel; Casasnovas, José María; Esteban, Mariano
2007-07-26

Digital.CSIC (Spain)

18

Subcellular forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vector

Vandermeeren, Andrée M.; Elena Gómez, Carmen; Patiño, Cristina; Domingo-Gil, Elena; Guerra, Susana; González, José Manuel

To identify the subcellular forms and biochemical events induced in human cells after HCV polyprotein expression, we have used a robust cell culture system based on vaccinia virus (VACV) that efficiently expresses in infected cells the structural and nonstructural proteins of HCV from genotype 1b (V...

DRIVER (Spanish)

19

Desarrollo de agentes inmunizantes contra el dengue/ Development of immunizing agents against dengue

López Antuñano, Francisco J.; Mota, Javier
2000-05-01

Resumen en español El complejo de los cuatro flavivirus del dengue es transmitido principalmente por el mosquito Aedes aegypti. Se han atribuido epidemias a la actividad de A. albopictus, A. polynesiensis y a varias especies del complejo A. scutellaris. Los factores de riesgo que determinan la probabilidad de enfermar o morir por dengue están relacionados tanto con el huésped (características genéticas, estado inmunitario, forma de vida y condiciones de salud, saneamiento básico de la (mas) vivienda y abastecimiento de agua potable) como con el virus (variabilidad genética de cepas entre y dentro de los serotipos, diferente capacidad patógena y distribución geográfica). A pesar de la falta de conocimiento sobre la inmunobiopatología del dengue, se han hecho importantes avances para conseguir una respuesta inmunitaria protectora con virus atenuados y con antígenos obtenidos por medio de tecnologías recombinantes. Desde los años 40, se ha intentado desarrollar vacunas contra el dengue. La inmunidad que se adquiere por infección natural es específica para cada serotipo y se han documentado infecciones por tres serotipos diferentes en la misma persona, por lo que probablemente sea necesaria una vacuna tetravalente. En voluntarios se han probado vacunas contra los cuatro serotipos que han sido inmunógenas y seguras. Aunque las vacunas con virus atenuados son prometedoras, son necesarios nuevos estudios sobre su eficacia y seguridad. Actualmente están en curso estudios para producir vacunas contra el virus del dengue mediante tecnologías de ADN recombinante y otras técnicas de biología molecular, utilizando como antígenos proteínas estructurales (principalmente la glicoproteína E) y no estructurales. Con el mismo propósito se han usado varios vectores de expresión, como Escherichia coli, baculovirus, virus de la vacuna y virus de la fiebre amarilla. Lamentablemente, no se han obtenido resultados satisfactorios en el hombre. La necesidad de desarrollar vacunas eficaces contra el dengue tiene especial importancia si se toma en cuenta la magnitud del problema de la transmisión de los cuatro serotipos en el mundo. La inmunización efectiva contra el dengue contribuirá a su prevención y la relación costo-beneficio será positiva. El hecho de que el dengue endémico afecte a niños de corta edad hace necesaria su inmunización, aprovechando la oportunidad que ofrece el Programa Ampliado de Inmunización. Resumen en inglés The four serotypes of dengue flaviviruses are transmitted mainly by the Aedes aegypti mosquito, and some epidemics have been attributed to Ae. albopictus, Ae. polynesiensis, and various species of the Ae. scutellaris complex. The risk factors involved in dengue mortality and morbidity are related to the human host (genetic characteristics of infected persons; lifestyles, immune status, and health conditions of people; basic sanitation of dwellings; and water supply) and t (mas) o the virus (genetic variability between and among serotypes, different pathogenicities, and geographic distribution). Notwithstanding the lack of knowledge of the immunopathobiology of dengue fever, important advances have been made in terms of a protective immune response, using attenuated dengue viruses or antigens produced by means of recombinant technologies. Efforts have been made since the 1940s to develop dengue vaccines. Immunity acquired from natural infection is specific for each serotype, and as many as three different serotype infections have been reported in one individual. For this reason, a tetravalent vaccine may likely be needed. Candidate vaccines against the four serotypes have been tested in volunteers and have proven to be immunogenic and safe. Although attenuated live virus vaccines are promising, more study is needed regarding their effectiveness and safety. Currently, several studies are ongoing to develop dengue vaccines using antigens from structural proteins (particularly E glycoprotein) and nonstructural proteins, with recombinant DNA technology and other biomolecular technologies. With the same goal, various expression vectors are being used, including Escherichia coli, baculovirus, vaccinia virus, and yellow fever virus. Unfortunately, no satisfactory results have been obtained in humans. The need for effective dengue vaccines is great, given the serious worldwide problem of the transmission of the four serotypes. Effective immunization against dengue would contribute to its prevention, with a positive cost-benefit relationship. Endemic dengue affects young children, and they should be immunized through the Expanded Program on Immunization.

Scientific Electronic Library Online (Spanish)

20

LA PROTEÍNA VIRAL VP6 DE ROTAVIRUS COINMUNOPRECIPITA CON HSC70 EN CÉLULAS MA104/ The viral protein VP6 of rotavirus coinmunoprecipated with HSC70 in cels MA104

Rodríguez, Luz Stella; Guerrero F, Carlos Arturo
2006-03-01

Resumen en español Introducción: los rotavirus son la principal causa de gastroenteritis en niños menores de cinco años. Hasta el momento se desconoce cómo entran estos virus a la célula huésped. La proteína de choque térmico, HSC70 se ha visto involucrada en la entrada del virus, sin embargo no se han relacionado bien todos los sitios de unión entre las proteínas virales del rotavirus y la HSC70. Objetivos: el propósito de este trabajo fue determinar cuáles proteínas virales d (mas) el rotavirus son responsables de la unión de la proteína de choque térmico, HSC70. Material y métodos: se realizaron ensayos de coinmunoprecipitación utilizando lisados de células infectadas así como proteínas virales recombinantes. Estos ensayos se revelaron mediante SDS-PAGE y Western blot utilizando anticuerpos policlonales que reconocen las proteínas del rotavirus. Resultados. En los experimentos realizados se encontró que la proteína viral VP6 coinmunoprecipita con HSC70 en las células MA104 durante la infección con rotavirus. La VP6, producida con vaccinia recombinante en MA104, también coinmunoprecipitó con HSC70. Conclusión. La proteína VP6 de rotavirus interacciona con la proteína HSC70 en lisados de células MA104 infectadas con rotavirus. La unión de la VP6 recombinante a la HSC70 sugiere que la interacción de estas proteínas es independiente de otras proteínas virales. Resumen en inglés Introduction: Rotaviruses are the main cause of gastroenteritis in children under five years old. At this moment is unknown how these viruses entry to host cell. The heat shock cognate protein HSC70 has been involved in rotavirus cell entry. However, the relationship between rotavirus proteins and HSC70 has not been established. Objectives: the purpose of this work was to determine wich rotaviruses proteins interact with HSC70. Material and methods: coimmunoprecipitation (mas) assays were done on a rotavirus infected supernatant and recombinant viral proteins. These assays were revealed by SDS-PAGE and Western blot using policlonal antibodys against rotavirus structural proteins. Results: data show that viral protein VP6 coimmunoprecipated with HSC70 in MA104 cells during infection. Recombinant vaccinia of VP6 produced in MA104 cells also coimmunoprecipitated with HSC70. Conclusions: these results suggest the interaction between VP6 and HSC70 during rotavirus infection. Furthermore, this union may be independent of other rotaviruses proteins.

Scientific Electronic Library Online (Spanish)

21

Vectores en los que se inserta el gen C7L y uso de los mismos en la fabricación de vacunas y de composiciones para terapia génica

Nájera García, José Luis; Gómez Rodríguez, Carmen Elena; Esteban Rodríguez, Mariano
2007-11-22

Digital.CSIC (Spain)

22

Vacuna para la protección de animales frente a Leishmania.

Larraga, Vicente; González Aseguinolaza, G.; Ramiro Ibáñez, M. J.; Castillo Hernández, J. A.; Lucientes, J.
2010-03-11

Digital.CSIC (Spain)

25

Subcellular forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vector

Vandermeeren, Andrée M.; Elena Gómez, Carmen; Patiño, Cristina; Domingo-Gil, Elena; Guerra, Susana; González, José Manuel; Esteban, Mariano
2008-09-15

Digital.CSIC (Spain)

26

Interleukin 2 abrogates the nonresponsive state of T cells expressing a forbidden T cell receptor repertoire and induces autoimmune disease in neonatally thymectomized mice

Andreu-Sánchez, Jose L.; Moreno de Alborán, Ignacio; Marcos, Miguel A. R.; Sánchez-Movilla, Arsenio; Martínez-Alonso, Carlos; Kroemer, Guido
1991-06-01

Digital.CSIC (Spain)

28

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1(BX08) gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B

Gómez, Carmen E.; Nájera García, José Luis; Pérez Jiménez, Eva; Jiménez, Victoria; Wagner, Ralf; Graf, Marcus; Frachette, Marie-Joelle; Liljeström, Peter; Pantaleo, Giuseppe; Esteban, Mariano
2006-10-16

Digital.CSIC (Spain)

29

Expression of normal and truncated forms of human endoglin

Raab, Ulla; Velasco, Beatriz; Lastres, Pedro; Letamendía, Ainhoa; Calés Bourdet, Carmela; Langa, Carmen; Tapia, Esther; López-bote, Juan Pedro; Páez, Eduardo; Bernabeu, Carmelo
1999-05-01

Digital.CSIC (Spain)

30

Emerging biological functions of the Vaccinia-Related Kinase (VRK) family

Klerkx, Elke P. F.; Lazo, Pedro A.; Askjaer, Peter
2009-06-01

Digital.CSIC (Spain)

31

Differential Cleavage of eIF4GI and eIF4GII in Mammalian Cells

Castelló, Alfredo; Alvarez, Enrique; Carrasco, Luis

Article available at http://www.jbc.org/cgi/content/abstract/M604340200v1 | Two isoforms of the translation initiation factor eIF4G, eIF4GI and eIF4GII, have been described in eukaryotic cells. The exact function of each isoform during the initiation of protein synthesis is still under investigation...

DRIVER (Spanish)

32

Differential Cleavage of eIF4GI and eIF4GII in Mammalian Cells

Castelló, Alfredo; Alvarez, Enrique; Carrasco, Luis
2006-09-07

Digital.CSIC (Spain)

33

Differential CD4+ versus CD8+ T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates

Mooij, Petra; Balla-Jhagjhoorsingh, Sunita S.; Koopman, Gerrit; Beenhakker, Niels; Van Haaften, Patricia

14 pages, 8 figures.-- PMID: 18184713 [PubMed].-- Supplementary material available: Table S1: DNA sequence of MVA-89.6p-SIVgpn in the TK viral locus.-- Printed version published on Mar 2008. | Poxvirus vectors have proven to be highly effective for boosting immune responses in diverse vaccine settin...

DRIVER (Spanish)

34

Differential CD4+ versus CD8+ T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates

Mooij, Petra; Balla-Jhagjhoorsingh, Sunita S.; Koopman, Gerrit; Beenhakker, Niels; Van Haaften, Patricia; Baak, Ilona; Nieuwenhuis, Ivonne G.; Kondova, Ivanela; Wagner, Ralf; Wolf, Hans; Gómez, Carmen E.; Nájera García, José Luis; Jiménez, Victoria; Esteban, Mariano; Heeney, Jonathan L.
2008-01-09

Digital.CSIC (Spain)

35

Cloning, Expression, and Characterization of a Recombinant Gilthead Seabream Growth Hormone

Martínez-Barberá, Juan P.; Pendón, Carlos; Rodríguez Martínez, Ramón B.; Pérez-Sánchez, Jaume; Valdivia, Manuel M.
1994-11-01

Digital.CSIC (Spain)

36

Antiviral activity of lauryl gallate against animal viruses.

Hurtado, Carolina; Bustos, Maria José; Sabina, Prado; Nogal París, María Luisa; Granja, Aitor G.; González, Maria E.; González Porque, Pedro; Revilla Novella, Yolanda; Carrascosa, Angel L.
2008-01-01

Digital.CSIC (Spain)

37

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

Harari, Alexandre; Bart, Pierre-Alexandre; Stöhr, Wolfgang; Tapia, Gonzalo; García, Miguel; Medjitna-Rais, Emmanuelle

15 pages, 8 figures.-- PMID: 18195071 [PubMed].-- PMCID: PMC2234371. | The EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen comprising recombinant DNA and the poxvirus vector NYVAC, both expressing a common immunogen consisting of Env, Gag, Pol, and Nef ...

DRIVER (Spanish)

38

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

Harari, Alexandre; Bart, Pierre-Alexandre; Stöhr, Wolfgang; Tapia, Gonzalo; García Cabezas, Miguel Ángel; Medjitna-Rais, Emmanuelle; Burnet, Séverine; Cellerai, Cristina; Erlwein, Otto; Barber, Tristan; Moog, Christiane; Liljeström, Peter; Wagner, Ralf; Wolf, Hans; Kraehenbuhl, Jean-Pierre; Esteban, Mariano; Heeney, Jonathan L.; Frachette, Marie-Joelle; Tartaglia, James; McCormack, Sheena; Babiker, Abdel; Weber, Jonathan; Pantaleo, Giuseppe
2008-01-14

Digital.CSIC (Spain)